Shares of Revance Therapeutics Inc (NASDAQ:RVNC) have received an average recommendation of “Buy” from the fourteen analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $49.71.

A number of equities research analysts have weighed in on RVNC shares. Cantor Fitzgerald set a $50.00 price objective on Revance Therapeutics and gave the company a “buy” rating in a report on Tuesday, May 29th. BidaskClub raised Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 13th. Zacks Investment Research raised Revance Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Wednesday, July 11th. Finally, ValuEngine raised Revance Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd.

NASDAQ RVNC opened at $23.55 on Tuesday. Revance Therapeutics has a 52-week low of $22.25 and a 52-week high of $37.45. The stock has a market cap of $977.01 million, a P/E ratio of -5.87 and a beta of 1.28.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.02). Revance Therapeutics had a negative return on equity of 63.30% and a negative net margin of 13,690.62%. The company had revenue of $0.69 million for the quarter, compared to analysts’ expectations of $0.93 million. analysts expect that Revance Therapeutics will post -3.9 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. American International Group Inc. boosted its holdings in Revance Therapeutics by 11.4% in the 1st quarter. American International Group Inc. now owns 17,205 shares of the biopharmaceutical company’s stock valued at $530,000 after purchasing an additional 1,765 shares in the last quarter. Nottingham Advisors Inc. boosted its stake in shares of Revance Therapeutics by 17.7% during the 2nd quarter. Nottingham Advisors Inc. now owns 13,312 shares of the biopharmaceutical company’s stock worth $365,000 after acquiring an additional 2,000 shares in the last quarter. Voya Investment Management LLC boosted its stake in shares of Revance Therapeutics by 19.6% during the 2nd quarter. Voya Investment Management LLC now owns 12,433 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 2,041 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Revance Therapeutics by 25.8% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 10,875 shares of the biopharmaceutical company’s stock worth $299,000 after acquiring an additional 2,232 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Revance Therapeutics by 12.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 20,446 shares of the biopharmaceutical company’s stock worth $630,000 after acquiring an additional 2,274 shares in the last quarter. 94.35% of the stock is currently owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.